Trial Information: This is an international Phase III trial of ofatumumab. 338 patients with relapsed or refractory indolent lymphoma, including follicular lymphoma, will be randomized to receive either bendamustine monotherapy or ofatumumab plus bendamustine (O-B), in eight 21-day cycles.
Background Information: Ofatumumab is a new humanized anti-CD20 monoclonal antibody, with the potential to replace the chimeric (mouse-human) antibody rituximab in treatment of B-cell lymphomas, including follicular lymphoma. Thus far it has predominantly been tested only in the relapsed/refractory setting. In this setting, most patients are already resistant to CD20-based drugs (due to exposure to rituximab), and ofatumumab has had only marginal effect.
That said, it is possible that there may be additional benefits in patients also (potentially) responsive to bendamustine. Your doctor may be able to discuss what researchers hope to establish in this trial.
Other ofatumumab and bendamustine trials are also ongoing in Canada. For more information, see the Clinical Trials page.
Canadian Locations: Halifax, NS; Toronto, ON
For more information, see ClinicalTrials.gov.
No comments:
Post a Comment